02:38:09 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Prenumeration

Kalender

2025-04-25 Årsstämma 2025
2025-02-26 Bokslutskommuniké 2024
2024-10-24 Kvartalsrapport 2024-Q3
2024-07-18 Kvartalsrapport 2024-Q2
2024-04-26 Ordinarie utdelning MAGLE 0.00 SEK
2024-04-25 Årsstämma 2024
2024-04-18 Kvartalsrapport 2024-Q1
2024-02-16 Bokslutskommuniké 2023
2023-10-25 Kvartalsrapport 2023-Q3
2023-07-18 Kvartalsrapport 2023-Q2
2023-04-27 Ordinarie utdelning MAGLE 0.00 SEK
2023-04-26 Årsstämma 2023
2023-02-16 Bokslutskommuniké 2022
2022-11-09 Kvartalsrapport 2022-Q3
2022-08-17 Kvartalsrapport 2022-Q2
2022-05-19 Ordinarie utdelning MAGLE 0.00 SEK
2022-05-17 Årsstämma 2022
2022-05-05 Kvartalsrapport 2022-Q1
2022-02-25 Bokslutskommuniké 2021
2021-12-14 Extra Bolagsstämma 2021
2021-11-16 Kvartalsrapport 2021-Q3
2021-08-17 Kvartalsrapport 2021-Q2
2021-05-14 Kvartalsrapport 2021-Q1
2021-05-03 Ordinarie utdelning MAGLE 0.00 SEK
2021-04-18 Årsstämma 2021
2021-02-25 Bokslutskommuniké 2020
2020-11-27 Extra Bolagsstämma 2020
2020-11-05 Kvartalsrapport 2020-Q3
2020-07-14 Kvartalsrapport 2020-Q2

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriMedicinteknik
Magle Chemoswed är verksamt inom läkemedelsbranschen. Bolaget är specialiserat inom utveckling av analytiska program. Produktportföljen är bred och inkluderar exempelvis program för intern uppföljning, process- samt systemhantering. Utöver huvudverksamheten erbjuds även service och tillhörande kringtjänster inom arbetsområdet. Verksamheten drivs globalt med störst närvaro inom den nordiska marknaden. Magle Chemoswed har sitt huvudkontor i Malmö.
2021-11-16 08:30:00

Magle Chemoswed Holding today reported financial results for the third quarter ended September 30, 2021, which are in line with expectations.

Q3 2021 AND OTHER RECENT BUSINESS ACCOMPLISHMENTS

  • Net sales amounted to 32,2 MSEK (28,8).
  • EBITDA equalled 4,9 MSEK (3,7).
  • Operating profit (EBIT) is 1,9 MSEK (1,1)
  • Profit after tax amounted to 1,5 MSEK (-0,4)
  • Earnings per share amounted to SEK 0,14 (-0,04) per share
  • Announced the recruitment of Simon Jegou as the Chief Strategy Officer
  • Announced the inclusion of the EmboCept® S product’s inclusion in leading treatment guidelines
  • Announced the transfer of the AXXO Woundgel to manufacturing operations

“Our third quarter performance demonstrates the strength of our strategy and diversified portfolio”, said Justin Pierce, chief executive officer of Magle Chemoswed. “We had a solid third quarter that delivered in line with expectations. We made significant advances on our technology products, progressing the development portfolio, and publishing clinical data in leading scientific journals supporting the increased use of our degradable starch microsphere technology. The CDMO services business area continued to stabilise and perform according to budget, with new projects and orders secured for the next quarter and early 2022”, added Justin Pierce.

FINANCIAL HIGHLIGHTS

 2021
July-Sept.
2020
July-Sept.
2021
Jan-Sept.
2020
Jan-Sept.
2020
Jan-Dec.
Net sales, TSEK32 24028 77996 205101 836142 337
EBITDA, TSEK4 9423 78112 49313 32916 193
EBITDA margin, %15%13%13%13%11%
Operating profit, TSEK1 9911 0953 7594 3294 526
Net profit/loss for the period, TSEK1 514-3823 0322 5111 819
Earnings per share, SEK 0,14-0,0380,2810,2510,24
Operating cash flow, TSEK69311 79518 93114 888-5 545
Operating cash flow per share, SEK 0,061,181,751-0,54
Equity ratio, %59%61%56%61%58,80%
Equity at period end, TSEK138 767115 840126 268115 840116 121
Return on Equity1,35%-0,41%2,68%3,56%2,10%
Return on Asset0,94%0,58%1,67%2,24%2,64%